Medical Inquiry

This medicinal product does not have a marketing authorisation. It has been given authorisation for temporary supply by the relevant National Health Regulatory Authority for active immunization against COVID-19 caused by SARS-CoV-2 in individuals within the authorized age range in designated countries.

Please note that the Pfizer COVID-19 mRNA vaccine (BNT162) might be an investigational product in some countries and currently not approved for use by the local Health Authority.

This form is for Health Care Professionals only. Adverse events should be reported.

To report a suspected adverse event or side effect related to the COVID-19 mRNA Vaccine BNT162b2, please use the link below:
COVID-19 mRNA Vaccine BNT162b2 Safety reporting site (The link clicked will take you to a separate site maintained by Pfizer).